CN104136026B - 包含mao靶向/探寻器部分的人神经胶质瘤治疗用化合物 - Google Patents

包含mao靶向/探寻器部分的人神经胶质瘤治疗用化合物 Download PDF

Info

Publication number
CN104136026B
CN104136026B CN201280064763.1A CN201280064763A CN104136026B CN 104136026 B CN104136026 B CN 104136026B CN 201280064763 A CN201280064763 A CN 201280064763A CN 104136026 B CN104136026 B CN 104136026B
Authority
CN
China
Prior art keywords
compound
mao
glioma
cells
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201280064763.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN104136026A (zh
Inventor
大卫·S·巴斯肯
马丁·阿伦·夏普
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
The Methodist Hospital
Original Assignee
The Methodist Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Methodist Hospital filed Critical The Methodist Hospital
Publication of CN104136026A publication Critical patent/CN104136026A/zh
Application granted granted Critical
Publication of CN104136026B publication Critical patent/CN104136026B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201280064763.1A 2011-10-31 2012-10-31 包含mao靶向/探寻器部分的人神经胶质瘤治疗用化合物 Expired - Fee Related CN104136026B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161553854P 2011-10-31 2011-10-31
US61/553,854 2011-10-31
PCT/US2012/062850 WO2013151584A1 (en) 2011-10-31 2012-10-31 Compound comprising a mao targeting/ seeker moiety for treating human gliomas

Publications (2)

Publication Number Publication Date
CN104136026A CN104136026A (zh) 2014-11-05
CN104136026B true CN104136026B (zh) 2018-03-02

Family

ID=47146760

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280064763.1A Expired - Fee Related CN104136026B (zh) 2011-10-31 2012-10-31 包含mao靶向/探寻器部分的人神经胶质瘤治疗用化合物

Country Status (9)

Country Link
US (1) US10555936B2 (cg-RX-API-DMAC7.html)
EP (2) EP2804604A1 (cg-RX-API-DMAC7.html)
JP (1) JP6118808B2 (cg-RX-API-DMAC7.html)
KR (1) KR102110794B1 (cg-RX-API-DMAC7.html)
CN (1) CN104136026B (cg-RX-API-DMAC7.html)
AU (1) AU2012376221A1 (cg-RX-API-DMAC7.html)
CA (1) CA2887928A1 (cg-RX-API-DMAC7.html)
HK (1) HK1204547A1 (cg-RX-API-DMAC7.html)
WO (1) WO2013151584A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6118808B2 (ja) 2011-10-31 2017-04-19 ザ メソジスト ホスピタル リサーチ インスティテュート ヒトグリオームを治療するためのmao標的化/探索部分を含む化合物
CN104710433B (zh) * 2014-01-23 2016-08-17 南京友怡医药科技有限公司 苯丁酸氮芥衍生物、制备方法及应用
US10807944B2 (en) * 2014-04-04 2020-10-20 University Of Florida Research Foundation, Inc. HDAC inhibitor compounds and methods of treatment
US12245355B2 (en) 2021-02-19 2025-03-04 Mevion Medical Systems, Inc. Gantry for a particle therapy system

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994029333A1 (en) * 1993-06-07 1994-12-22 The Wellcome Foundation Limited Immunoreactive reagents employing monoamine oxidase
WO1998022110A1 (en) * 1996-11-20 1998-05-28 Virginia Tech Intellectual Properties, Inc. Prodrugs for the selective inhibition of monoamine oxidase-b

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4913891A (en) * 1986-04-17 1990-04-03 The United States Of America As Represented By The United States Department Of Energy Positron emitter labeled enzyme inhibitors
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
US5612329A (en) 1995-06-05 1997-03-18 University Of Maryland At Baltimore Diaziridinylpolyamine anti-cancer agents
KR20010102486A (ko) 1999-03-03 2001-11-15 데이비드 엠 모이어 알케닐- 및 알키닐-함유 메탈로프로테아제 저해제
US6727361B2 (en) 2000-11-07 2004-04-27 Symyx Technologies, Inc. Phosphino substituted pyridine amine ligands
US6946479B2 (en) 2002-11-09 2005-09-20 The Procter & Gamble Company N-sulfonyl-4-methyleneamino-3-hydroxy-2-pyridones
US7943586B2 (en) 2003-06-09 2011-05-17 The Trustees Of The University Of Pennsylvania Antineoplastic agents targeted via glut transporters
EP1758887A1 (en) * 2004-05-14 2007-03-07 Pfizer Products Incorporated Pyrimidine derivatives for the treatment of abnormal cell growth
US7091205B2 (en) 2004-10-08 2006-08-15 Yu Show Fu Use of tetramethylpyrazine in the treatment of brain tumor
GB0513297D0 (en) 2005-06-29 2005-08-03 Glaxo Group Ltd Novel compounds
US20070275944A1 (en) 2006-04-05 2007-11-29 The Board Of Trustees Operating Michigan State University Antioxidants and methods of their use
AR070317A1 (es) * 2008-02-06 2010-03-31 Osi Pharm Inc Furo (3,2-c) piridina y tieno (3,2-c) piridinas
WO2009111278A2 (en) * 2008-02-29 2009-09-11 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof
EP2141163A1 (de) * 2008-07-02 2010-01-06 Bayer Schering Pharma AG Substituierte Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel
ES2668775T3 (es) * 2009-06-10 2018-05-22 Chugai Seiyaku Kabushiki Kaisha Compuestos tetracíclicos
US8293925B2 (en) * 2009-09-21 2012-10-23 Chemocentryx, Inc. Pyrrolidinone carboxamide derivatives
JP6118808B2 (ja) 2011-10-31 2017-04-19 ザ メソジスト ホスピタル リサーチ インスティテュート ヒトグリオームを治療するためのmao標的化/探索部分を含む化合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994029333A1 (en) * 1993-06-07 1994-12-22 The Wellcome Foundation Limited Immunoreactive reagents employing monoamine oxidase
WO1998022110A1 (en) * 1996-11-20 1998-05-28 Virginia Tech Intellectual Properties, Inc. Prodrugs for the selective inhibition of monoamine oxidase-b

Also Published As

Publication number Publication date
US10555936B2 (en) 2020-02-11
JP2014534227A (ja) 2014-12-18
KR102110794B1 (ko) 2020-05-15
US20140323513A1 (en) 2014-10-30
WO2013151584A1 (en) 2013-10-10
EP2804604A1 (en) 2014-11-26
CN104136026A (zh) 2014-11-05
EP3815685A2 (en) 2021-05-05
HK1204547A1 (en) 2015-11-27
JP6118808B2 (ja) 2017-04-19
KR20140128943A (ko) 2014-11-06
CA2887928A1 (en) 2013-10-10
AU2012376221A1 (en) 2014-06-19
EP3815685A3 (en) 2021-10-13

Similar Documents

Publication Publication Date Title
JP6652923B2 (ja) クロロトキシンコンジュゲート及びその使用方法
US8853151B2 (en) Pro-drug complexes and related methods of use
US20100248371A1 (en) Methods and compositions for modulating rad51 and homologous recombination
AU2013362757B2 (en) Radiosensitizer compounds for use in combination with radiation
US20130317101A1 (en) Singleton inhibitors of sumoylation enzymes and methods for their use
JP2019501225A (ja) B細胞リンパ腫2(bcl−2)及び関連タンパク質の阻害
US12377087B2 (en) Compounds for the treatment of cancer
US12186404B2 (en) Delta-opioid receptor targeted agent for molecular imaging and immunotherapy of cancer
CN104136026A (zh) 包含mao靶向/探寻器部分的人神经胶质瘤治疗用化合物
US20110152252A1 (en) Shiga toxin b-subunit/chemotherapeutics conjugates
CN106232115A (zh) 用于治疗抗性的癌症的预防或治疗性组合物
Hou et al. GSH-activatable camptothecin prodrug-loaded gold nanostars coated with hyaluronic acid for targeted breast cancer therapy via multiple radiosensitization strategies
JP2012012305A (ja) 抗がん剤の作用増強剤
ES2991018T3 (es) (N-(2-((2-bencilfenil)amino)-2-oxoetil)-L-naftamida) como agente terapéutico anticanceroso
US20140296265A1 (en) Method of Treating Lymphoma Using Pyridopyrimidinone Inhibitors of PI3K/mTOR
JP6382964B2 (ja) フタラジン誘導体
JP2014534227A5 (cg-RX-API-DMAC7.html)
US11325905B2 (en) Imidopiperidine compounds as inhibitors of human polynucleotide kinase phosphatase
HK40041905A (en) Compound comprising a mao targeting/seeker moiety for treating human gliomas
WO2022182655A2 (en) Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds and biological therapies including substituted camptothecins such as irinotecan and topotecan for the treatment of benign and neoplastic hyperproliferative disease conditions, infections, inflammatory and immunological diseases
CN121240859A (zh) 用于治疗健康状况的组合物和制备和使用小分子的方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
CI01 Publication of corrected invention patent application

Correction item: Applicant address

Correct: Texas, USA

False: Texas, USA

Number: 45

Volume: 30

CI02 Correction of invention patent application

Correction item: Applicant address

Correct: Texas, USA

False: Texas, USA

Number: 45

Page: The title page

Volume: 30

ERR Gazette correction

Free format text: DELETE

RECT Rectification
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20230310

Address after: Texas, USA

Patentee after: THE METHODIST Hospital

Address before: Texas, USA

Patentee before: THE METHODIST HOSPITAL Research Institute

TR01 Transfer of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20180302

CF01 Termination of patent right due to non-payment of annual fee